Compound load of copper and iron in the livers of pretreatment patients with Wilson's disease
Ai Harashima, Ai Hattori, Hisao Hayashi, Shinya Wakusawa, Atsuhiko Kusakabe, Yoshikazu Fujita, Minoru Tanaka, Motoyoshi Yano, Kentaro Yoshioka
{"title":"Compound load of copper and iron in the livers of pretreatment patients with Wilson's disease","authors":"Ai Harashima, Ai Hattori, Hisao Hayashi, Shinya Wakusawa, Atsuhiko Kusakabe, Yoshikazu Fujita, Minoru Tanaka, Motoyoshi Yano, Kentaro Yoshioka","doi":"10.1002/jtra.10054","DOIUrl":null,"url":null,"abstract":"Ceruloplasmin is a major ferroxidase in sera, and people with hypoceruloplasminemia might have iron load complications. We used histochemical and X-ray microanalysis techniques on pretreatment liver specimens from five patients with Wilson's disease. Serum levels of ceruloplasmin and ferritin were determined before chelation therapy. All the patients showed hypoceruloplasminemia ranging from 15 to 160 mg/L. Histo-chemical copper was positively stained in four of the five patients. Copper deposits were clearly observed in the hepatocyte lysosomes of one patient. High serum ferritin levels ranging from 188 to 400 ng/mL were found. Histochemical iron was positive in the livers of two patients. Iron-specific X-rays were positive in the hepatocyte lysosomes of all the patients. These findings suggest that compound load of copper and iron is a fundamental finding in the liver of Wilson's disease with hypoceruloplasminemia. Copper cytotoxicity is a primary target for chelation therapy, and iron load, if hepatotoxic, should be treated by phlebotomy. J. Trace Elem. Exp. 17:65–73, 2004. © 2004 Wiley-Liss, Inc.","PeriodicalId":101243,"journal":{"name":"The Journal of Trace Elements in Experimental Medicine","volume":"17 1","pages":"65-73"},"PeriodicalIF":0.0000,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/jtra.10054","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Trace Elements in Experimental Medicine","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jtra.10054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7
Wilson病预处理患者肝脏中铜和铁的复合负荷
铜蓝蛋白是血清中主要的铁氧化酶,低铜蓝蛋白血症患者可能会出现铁负荷并发症。我们使用组织化学和X射线显微分析技术对5例Wilson病患者的预处理肝脏标本进行了分析。螯合治疗前测定血清铜蓝蛋白和铁蛋白水平。所有患者均表现出15~160mg/L的低血细胞浆血症。五名患者中有四名患者的组织化学铜染色呈阳性。在一名患者的肝细胞溶酶体中可以清楚地观察到铜沉积。发现血清铁蛋白水平高,范围为188至400 ng/mL。两名患者的肝脏组织化学铁呈阳性。所有患者肝细胞溶酶体铁特异性X射线均呈阳性。这些发现表明,铜和铁的复合负荷是Wilson病伴低血蛋白血症的肝脏中的一个基本发现。铜的细胞毒性是螯合治疗的主要靶点,如果铁负荷具有肝毒性,则应通过静脉切开术进行治疗。J.Trace Elem。Exp.17:65-732004。©2004 Wiley-Liss,股份有限公司。
本文章由计算机程序翻译,如有差异,请以英文原文为准。